ReviewEBioMedicine2026
Modern xenotransplantation: rewiring glycan-mediated immunogenicity via genome-glycome convergence.
Review in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xenotransplantation addresses global organ shortages but faces species-specific glycan antigen barriers. Dominant xenoantigens (α-Gal, Neu5Gc, Sda) trigger hyperacute rejection via antibody-mediated immune cascades, complement activation, and thromboinflammation. Advances in precision genome editing, particularly CRISPR-Cas9 now facilitate the generation of multi-gene-edited pigs lacking GGTA1/CMAH/B4GALNT2 to eliminate these epitopes, co-expressing human complement/coagulation regulators to prolong graft survival. The systematic discovery of novel xenoantigens and validation of their immunogenicity, however, are still hampered by limited access to well-defined glycans and reliable functional assays. Emerging technologies, including advanced glycomics, glycoproteomics, and AI-driven prediction, are now accelerating the mapping and prioritisation of immunogenic glycan epitopes. This review synthesises three advances: glycan xenoantigens' immunodominant roles, multi-gene porcine models, and glycomics-driven epitope decoding. These discoveries directly inform next-generation genetic edits and clinical immune monitoring. Convergence of glycobiology, genome engineering, and multi-omics accelerates clinical translation, offering a roadmap for developing rejection-free organs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.